Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , and Seattle Genetics, Inc. today announced the initiation of an international phase 3 clinical trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in patients with previously untreated advanced Hodgkin lymphoma .
